Additionally, since BTK is upstream of the PKCβ signaling pathway, it is possible that ibrutinib, a BTK inhibitor approved for treatment of CLL [12], will also render CLL cells sensitive to ATO in the presence of stroma. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.